Similar to NKG2D-CD16, our NKG2D-CD3 construct showed a profound anti-sarcoma activity as revealed by T cell activation, degranulation, IFNγ and Perforin secretion as well as target cell lysis. This evidence concerns the gene KLRK1 and sarcoma.